Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 53, 2940-2943, July 1, 1993]
© 1993 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ito, T.
Right arrow Articles by Akiyama, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ito, T.
Right arrow Articles by Akiyama, M.

In Vitro Irradiation Is Able to Cause RET Oncogene Rearrangement

Takashi Ito, Toshio Seyama, Keisuke S. Iwamoto, Tomonori Hayashi, Terumi Mizuno, Naohiro Tsuyama, Kiyohiko Dohi, Nori Nakamura and Mitoshi Akiyama1

Department of Radiobiology, Radiation Effects Research Foundation, 5-2 Hijiyama Park, Minami-ku, Hiroshima 732 [T. I., T. S., T. H., T. M., K. S. I., N. T., N. N., M. A.] Second Department of Surgery, Hiroshima University School of Medicine, 1-2-3 Kasumi-cho, Minami-ku, Hiroshima 734 [K. D.], Japan

Elevated risk of thyroid cancers among the atomic bomb survivors as compared to the nonexposed population suggests that some genetic events related to thyroid cancer must be caused by ionizing radiation. Accordingly, inducibility of RET oncogene rearrangements, i.e., the generation of the RET-PTC oncogene, specific for thyroid cancer, was investigated among human undifferentiated thyroid carcinoma cells (8505C), which do not have RET oncogene rearrangement, after 0, 10, 50, and 100 Gy of in vitro X-irradiation by means of reverse transcription polymerase chain reaction. After testing 10s cells at each dose point, 3 independent samples obtained with 50 Gy of X-irradiation and 6 independent samples obtained with 100 Gy of X-irradiation showed a rearranged RET oncogene amplified band. No rearranged transcripts were obtained from cells irradiated with 0 or 10 Gy. All of the transcripts were sequenced and found to contain the D10S170 and RET sequence. Interestingly, two types of rearrangements were included in these transcripts: one is specific for thyroid cancer and the other, which contains a 150-base pair insert, is atypical, not usually seen in vivo. This insert was found to be the exon of D10S170. Furthermore, in fibrosarcoma cells (HT1080), X-irradiation also induced RET oncogene rearrangements, which included the same two types of rearrangements observed in the X-irradiated thyroid cells (8505C). These results are in favor of the hypothesis that some radiation-induced thyroid cancers, including those among atomic bomb survivors, might have developed when a growth advantage was obtained through a specific form of RET oncogene rearrangement induced by radiation exposure.

1 To whom requests for reprints should be addressed.

Received 3/22/93. Accepted 5/19/93.




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
G. Riesco-Eizaguirre and P. Santisteban
New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy
Endocr. Relat. Cancer, December 1, 2007; 14(4): 957 - 977.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. Santoro, R. M. Melillo, and A. Fusco
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.
Eur. J. Endocrinol., November 1, 2006; 155(5): 645 - 653.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
Endocr. Rev., August 1, 2006; 27(5): 535 - 560.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
M Xing
BRAF mutation in thyroid cancer
Endocr. Relat. Cancer, June 1, 2005; 12(2): 245 - 262.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
E Puxeddu, J A Knauf, M A Sartor, N Mitsutake, E P Smith, M Medvedovic, C R Tomlinson, S Moretti, and J A Fagin
RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response
Endocr. Relat. Cancer, June 1, 2005; 12(2): 319 - 334.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. M. Caudill, Z. Zhu, R. Ciampi, J. R. Stringer, and Y. E. Nikiforov
Dose-Dependent Generation of RET/PTC in Human Thyroid Cells after in Vitro Exposure to {gamma}-Radiation: A Model of Carcinogenic Chromosomal Rearrangement Induced by Ionizing Radiation
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2364 - 2369.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
J Di Cristofaro, V Vasko, V Savchenko, S Cherenko, A Larin, M D Ringel, M Saji, M Marcy, J F Henry, P Carayon, et al.
ret/PTC1 and ret/PTC3 in thyroid tumors from Chernobyl liquidators: comparison with sporadic tumors from Ukrainian and French patients
Endocr. Relat. Cancer, March 1, 2005; 12(1): 173 - 183.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
J A Fagin
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy
J. Endocrinol., November 1, 2004; 183(2): 249 - 256.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. A. Fagin
Challenging Dogma in Thyroid Cancer Molecular Genetics--Role of RET/PTC and BRAF in Tumor Initiation
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4264 - 4266.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Puxeddu, S. Moretti, R. Elisei, C. Romei, R. Pascucci, M. Martinelli, C. Marino, N. Avenia, E. D. Rossi, G. Fadda, et al.
BRAFV599E Mutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2414 - 2420.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Puxeddu, N. Mitsutake, J. A. Knauf, S. Moretti, H. W. Kim, K. A. Seta, D. Brockman, L. Myatt, D. E. Millhorn, and J. A. Fagin
Microsomal Prostaglandin E2 Synthase-1 Is Induced by Conditional Expression of RET/PTC in Thyroid PCCL3 Cells through the Activation of the MEK-ERK Pathway
J. Biol. Chem., December 26, 2003; 278(52): 52131 - 52138.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
J. Wang, J. A. Knauf, S. Basu, E. Puxeddu, H. Kuroda, M. Santoro, A. Fusco, and J. A. Fagin
Conditional Expression of RET/PTC Induces a Weak Oncogenic Drive in Thyroid PCCL3 Cells and Inhibits Thyrotropin Action at Multiple Levels
Mol. Endocrinol., July 1, 2003; 17(7): 1425 - 1436.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
D. W. Kim, J. H. Hwang, J. M. Suh, H. Kim, J. H. Song, E. S. Hwang, I. Y. Hwang, K. C. Park, H. K. Chung, J. M. Kim, et al.
RET/PTC (Rearranged in Transformation/Papillary Thyroid Carcinomas) Tyrosine Kinase Phosphorylates and Activates Phosphoinositide-Dependent Kinase 1 (PDK1): An Alternative Phosphatidylinositol 3-Kinase-Independent Pathway to Activate PDK1
Mol. Endocrinol., July 1, 2003; 17(7): 1382 - 1394.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. A. Fagin
Perspective: Lessons Learned from Molecular Genetic Studies of Thyroid Cancer--Insights into Pathogenesis and Tumor-Specific Therapeutic Targets
Endocrinology, June 1, 2002; 143(6): 2025 - 2028.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Cetta, M. Gori, G. Montalto, M. Zuckermann, and P. Toti
Different Significance of ret/PTC1 and ret/PTC3 Rearrangements in Thyroid Carcinogenesis: Lesson from Two Subgroups of Patients with Papillary Thyroid Carcinomas Showing the Highest Incidence of ret/PTC Activation
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1429 - 1429.
[Full Text]


Home page
ScienceHome page
M. N. Nikiforova, J. R. Stringer, R. Blough, M. Medvedovic, J. A. Fagin, and Y. E. Nikiforov
Proximity of Chromosomal Loci That Participate in Radiation-Induced Rearrangements in Human Cells
Science, October 6, 2000; 290(5489): 138 - 141.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
G. A. Thomas, H. Bunnell, H. A. Cook, E. D. Williams, A. Nerovnya, E. D. Cherstvoy, N. D. Tronko, T. I. Bogdanova, G. Chiappetta, G. Viglietto, et al.
High Prevalence of RET/PTC Rearrangements in Ukrainian and Belarussian Post-Chernobyl Thyroid Papillary Carcinomas: A Strong Correlation between RET/PTC3 and the Solid-Follicular Variant
J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4232 - 4238.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
J. A. Knauf, R. Elisei, D. Mochly-Rosen, T. Liron, X.-N. Chen, R. Gonsky, J. R. Korenberg, and J. A. Fagin
Involvement of Protein Kinase Cepsilon (PKCepsilon ) in Thyroid Cell Death. A TRUNCATED CHIMERIC PKCepsilon CLONED FROM A THYROID CANCER CELL LINE PROTECTS THYROID CELLS FROM APOPTOSIS
J. Biol. Chem., August 13, 1999; 274(33): 23414 - 23425.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1993 by the American Association for Cancer Research.